No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney and in vitro data suggest that it is a substrate of the renal transporters OAT3/OAT1. A clinically relevant drug interaction is unlikely as meropenem has a higher affinity for OAT3 whereas tenofovir is primarily excreted via OAT1 and emtricitabine is excreted by different renal transporters.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking